Treos Bio Limited news

LONDON, June 27, 2022– Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced that the first patient has been dosed in the OBERTO 301 Phase 2 trial of PolyPEPI1018, the Company’s lead product candidate, in combination with atezolizumab, Roche’s PD-L1 inhibitor, for the treatment of patients with late-stage microsatellite stable

LONDON, February 7, 2022– Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced that the first patient has been dosed in the OBERTO 201 Phase 1b trial of PolyPEPI1018, the Company’s lead product candidate, as an add-on to standard-of-care third-line chemotherapy (TAS-102) for the treatment of patients with late-stage microsatellite

LONDON, August 18, 2021– Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop both precision off-the-shelf and personalized peptide immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PolyPEPI1018, the Company’s lead product candidate, as an add-on to third-line chemotherapy (TAS

LONDON, July 7, 2021– Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop both precision off-the-shelf and personalized peptide cancer immunotherapies, today announced a clinical collaboration with Roche in which Treos will evaluate the combination of PolyPEPI1018, its lead product candidate, and atezolizumab, Roche’s PD-L1-inhibitor, in patients with late stage microsatellite sta